Knight Therapeutics (TSE:GUD) Reaches New 52-Week Low at $5.01

Knight Therapeutics Inc. (TSE:GUDGet Rating)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as C$5.01 and last traded at C$5.02, with a volume of 29553 shares traded. The stock had previously closed at C$5.07.

Knight Therapeutics Stock Performance

The company has a quick ratio of 1.79, a current ratio of 2.46 and a debt-to-equity ratio of 4.57. The company has a 50 day moving average of C$5.16 and a 200 day moving average of C$5.30. The firm has a market cap of C$576.64 million, a price-to-earnings ratio of -26.58, a PEG ratio of -1,013.50 and a beta of 0.51.

About Knight Therapeutics

(Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

Read More

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.